)

CVRx (CVRX) investor relations material
CVRx Canaccord Genuity’s 45th Annual Growth Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Market Opportunity and Therapy Overview
Barostim is the first neuromodulation therapy for heart failure, targeting a $2.2B annual U.S. market with a well-defined, underserved patient population and few competitors.
Heart failure affects over 6 million people in the U.S., with high hospitalization rates, limited effectiveness from current drug therapies and CRT, and projected annual costs of $70B by 2030.
Barostim is indicated for patients not adequately helped by drugs, addressing the "forgotten middle" and supported by new consensus guidelines recommending device therapy after 3–6 months of unsuccessful medical management.
The device is minimally invasive, implanted in a 45–60 minute outpatient procedure, is entirely extravascular, and has a 97% freedom from significant complications.
Clinical data show Barostim delivers durable, significant improvements in quality of life and exercise capacity, with a 94% responder rate and strong signals for reduced hospitalizations and mortality.
Clinical and Real-World Evidence
Quadruple drug therapy improves survival but has minimal impact on quality of life, with only 1% of patients reaching optimal dosing and over 40% discontinuing within a year.
Barostim showed a twofold improvement in exercise capacity and quality of life compared to standard drug therapies, as evidenced in the BeAT-HF trial.
The BeAT-HF trial indicated a 34% relative reduction in all-cause death, LVAD, or transplant over more than four years, though this was not a powered endpoint.
Real-world data from 2021–2023 showed an 85% reduction in hospital and emergency department visits post-Barostim implant.
Most heart failure patients value symptom improvement over longevity, with 65% willing to accept shorter life for fewer symptoms.
Commercial Strategy and Organizational Changes
The go-to-market strategy focuses on building a specialized sales team, developing sustainable Barostim programs, deepening adoption at select centers, and systematically addressing barriers of awareness, evidence, and access.
41% of quota-carrying sales reps are new in 2023 or 2025, causing short-term disruption but expected to drive long-term growth as onboarding and training progress.
Senior management and sales team have been streamlined, reducing direct reports and aiming for a scalable, high-competency leadership structure.
The sales approach has evolved to include select tier 3 and 4 accounts, optimizing territory potential and leveraging pragmatic entry strategies at academic centers.
Execution and productivity of the new sales force are the current focus, with expectations for improved results over the next two quarters.
Next CVRx earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage